公开(公告)号：US20230119816A1

公开(公告)日：2023-04-20

申请号：US18081476

申请日：2022-12-14

Applicant: CELL CURE NEUROSCIENCES LTD.

Inventor： Nir Netzer ,  Ofer Wiser ,  Bat Shahaf ,  Orit Gamburg ,  Lior Rosenberg Belmaker ,  Dana Hayoun Neeman ,  Osnat Bohana Kashtan

IPC: A01N1/02 ,  A61K9/00 ,  A61K35/30 ,  A61K47/02 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26

Abstract: Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries. A method of formulating human RPE cells for administration to a subject directly after thawing and of formulating RPE cell therapy compositions for cryopreservation and administration of the cryopreserved composition to a subject subsequent to thawing are also presented. In another aspect, the RTA composition may be formulated as a thaw and inject (TAI) composition, whereby the composition is administered by injection subsequent to thawing.

公开(公告)号：US20240285693A1

公开(公告)日：2024-08-29

申请号：US18424000

申请日：2024-01-26

Applicant: Cell Cure Neurosciences Ltd.

Inventor： Dana Hayoun Neeman ,  Ofer Wiser ,  Ravid Tikotzki ,  Lilach Alon

IPC: A61K35/30 ,  C12N5/079

CPC classification number: A61K35/30 ,  C12N5/0621 ,  C12N2501/15 ,  C12N2506/02 ,  C12N2531/00

Abstract: Presented herein are methods and compositions for expanding RPE cells with the use of a suspendable cell support matrix. Also provided are pharmaceutical compositions containing RPE cells, and methods of treating an eye disorder or disease using RPE cells.

公开(公告)号：US20220408719A1

公开(公告)日：2022-12-29

申请号：US17893977

申请日：2022-08-23

Applicant: CELL CURE NEUROSCIENCES LTD.

Inventor： Nir Netzer ,  Ofer Wiser ,  Bat Shahaf ,  Orit Gamburg ,  Lior Rosenberg Belmaker ,  Dana Hayoun Neeman ,  Osnat Bohana Kashtan

IPC: A01N1/02 ,  A61K9/00 ,  A61K35/30 ,  A61K47/02 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26

Abstract: Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries. A method of formulating human RPE cells for administration to a subject directly after thawing and of formulating RPE cell therapy compositions for cryopreservation and administration of the cryopreserved composition to a subject subsequent to thawing are also presented. In another aspect, the RTA composition may be formulated as a thaw and inject (TAI) composition, whereby the composition is administered by injection subsequent to thawing.